Content
May 2023, Volume 21, Issue 3
- 361-364 Global Pull Incentives for Better Antibacterials: The UK Leads the Way
by Kevin Outterson & John H. Rex - 365-372 Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?
by Colm Leonard & Nick Crabb & David Glover & Sophie Cooper & Jacoline Bouvy & Milena Wobbe & Mark Perkins - 373-384 The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework
by Laura Vallejo-Torres - 385-394 An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology
by Holly L. Cranmer & Gemma E. Shields & Ash Bullement - 395-403 Stakeholder Engagement in the Development of Public Health Economic Models: An Application to Modelling of Minimum Unit Pricing of Alcohol in South Africa
by N. K. Gibbs & C. Angus & S. Dixon & C. D. H. Parry & P. S. Meier - 405-418 Discrete Choice Experiments in Health State Valuation: A Systematic Review of Progress and New Trends
by Haode Wang & Donna L. Rowen & John E. Brazier & Litian Jiang - 419-440 A Systematic Review of Health Economic Evaluations and Budget Impact Analyses to Inform Healthcare Decision-Making in Central America
by Carlos Rojas-Roque & Alfredo Palacios - 441-466 The Impact of Value-Based Payment Models for Networks of Care and Transmural Care: A Systematic Literature Review
by Diogo L. L. Leao & Henricus-Paul Cremers & Dennis Veghel & Milena Pavlova & Wim Groot - 467-475 Use of Decision-Analytic Modelling to Assess the Cost-Effectiveness of Diagnostic Imaging of the Spine, Shoulder, and Knee: A Scoping Review
by Sean Docking & Lan Gao & Zanfina Ademi & Christian Bonello & Rachelle Buchbinder - 477-487 Medication Adherence and Healthcare Costs in Chronically Ill Patients Using German Claims Data
by Johannes Wendl & Andreas Simon & Martin Kistler & Jana Hapfelmeier & Antonius Schneider & Alexander Hapfelmeier - 489-499 Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis
by Yawen Jiang & Shan Jiang & Limin Li & Si Shi & Mincai Li & Lei Si - 501-510 The Impact of Suboxone’s Market Exclusivity on Cost of Opioid Use Disorder Treatment
by Meghan McGee & Kellia Chiu & Rahim Moineddin & Abhimanyu Sud - 511-522 Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand
by Waranya Rattanavipapong & Chittawan Poonsiri & Wanrudee Isaranuwatchai & Sopon Iamsirithaworn & Jutarat Apakupakul & Chaninan Sonthichai & Rungrueng Kitphati & Yot Teerawattananon - 523-532 Measurement of Health-Related Quality of Life from Conception to Postpartum Using the EQ-5D-5L Among a National Sample of US Pregnant and Postpartum Adults
by Annette K. Regan & Pallavi Aytha Swathi & Marcianna Nosek & Ning Yan Gu
March 2023, Volume 21, Issue 2
- 155-166 Development of an Instrument for the Assessment of Health-Related Multi-sectoral Resource Use in Europe: The PECUNIA RUM
by Irina Pokhilenko & Luca M. M. Janssen & Aggie T. G. Paulus & Ruben M. W. A. Drost & William Hollingworth & Joanna C. Thorn & Sian Noble & Judit Simon & Claudia Fischer & Susanne Mayer & Luis Salvador-Carulla & Alexander Konnopka & Leona Hakkaart van Roijen & Valentin Brodszky & A-La Park & Silvia M. A. A. Evers - 167-193 The Role of Mental Health on Workplace Productivity: A Critical Review of the Literature
by Claire Oliveira & Makeila Saka & Lauren Bone & Rowena Jacobs - 195-204 Headroom Analysis for Early Economic Evaluation: A Systematic Review
by Esther A. Boudewijns & Thomas M. Otten & Mariam Gobianidze & Bram L. Ramaekers & Onno C. P. Schayck & Manuela A. Joore - 205-224 Analysing the Efficiency of Health Systems: A Systematic Review of the Literature
by Rahab Mbau & Anita Musiega & Lizah Nyawira & Benjamin Tsofa & Andrew Mulwa & Sassy Molyneux & Isabel Maina & Julie Jemutai & Charles Normand & Kara Hanson & Edwine Barasa - 225-242 The Cost-Effectiveness of Adjunctive Lifestyle Interventions for the Management of Cancer: A Systematic Review
by Andrew Gallagher & Violetta Shersher & Duncan Mortimer & Helen Truby & Terry Haines - 243-251 The False Economy of Seeking to Eliminate Delayed Transfers of Care: Some Lessons from Queueing Theory
by Richard M. Wood & Alison L. Harper & Zehra Onen-Dumlu & Paul G. Forte & Martin Pitt & Christos Vasilakis - 253-262 A Guideline-Implementation Intervention to Improve the Management of Low Back Pain in Primary Care: A Difference-in-Difference-in-Differences Analysis
by Ross Wilson & Yana Pryymachenko & J. Haxby Abbott & Sarah Dean & James Stanley & Sue Garrett & Fiona Mathieson & Anthony Dowell & Ben Darlow - 263-273 An Economic Model for Estimating Trial Costs with an Application to Placebo Surgery Trials
by Chris Schilling & Michelle Tew & Samantha Bunzli & Cade Shadbolt & L. Stefan Lohmander & Zsolt J. Balogh & Francesco Paolucci & Peter F. Choong & Michelle M. Dowsey & Philip Clarke - 275-287 Population-Level Impact of Omitting Axillary Lymph Node Dissection in Early Breast Cancer Women: Evidence from an Economic Evaluation in Germany
by Hoa Thi Nguyen & Manuela Allegri & Jörg Heil & André Hennigs - 289-303 EQ-5D-5L Population Norms for Italy
by Michela Meregaglia & Francesco Malandrini & Aureliano Paolo Finch & Oriana Ciani & Claudio Jommi - 305-314 The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals
by Patricia G. Synnott & Dominic Voehler & Daniel E. Enright & Stacey Kowal & Daniel A. Ollendorf - 315-325 Cost-Effectiveness and Value of Information Analysis of an Ambient Intelligent Geriatric Management (AmbIGeM) System Compared to Usual Care to Prevent Falls in Older People in Hospitals
by Clarabelle T. Pham & Renuka Visvanathan & Mark Strong & Edward C. F. Wilson & Kylie Lange & Joanne Dollard & Damith Ranasinghe & Keith Hill & Anne Wilson & Jonathan Karnon - 327-346 An Item-Response Mapping from General Health Questionnaire Responses to EQ-5D-3L Using a General Population Sample from England
by Edward J. D. Webb - 347-359 A Comparative Analysis of Anticancer Drug Appraisals Including Managed Entry Agreements in South Korea and England
by Iyn-Hyang Lee & Karen Bloor & Eun-Young Bae
January 2023, Volume 21, Issue 1
- 5-10 Family Spillover Effects: Are Economic Evaluations Misrepresenting the Value of Healthcare Interventions to Society?
by Ashley A. Leech & Pei-Jung Lin & Brittany D’Cruz & Susan K. Parsons & Tara A. Lavelle - 11-22 Development of a Health Technology Assessment Quality Appraisal Checklist (HTA-QAC) for India
by Yashika Chugh & Pankaj Bahuguna & Aamir Sohail & Kavitha Rajsekar & V. R. Muraleedharan & Shankar Prinja - 23-30 Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance
by Jake T. W. Williams & Katy J. L. Bell & Rachael L. Morton & Mbathio Dieng - 31-38 Valuation of Costs in Health Economics During Financial and Economic Crises: A Case Study from Lebanon
by Jalal Dahham & Ingrid Kremer & Mickaël Hiligsmann & Kamal Hamdan & Abdallah Nassereddine & Silvia M. A. A. Evers & Rana Rizk - 39-51 A Systematic Review of Kidney Transplantation Decision Modelling Studies
by Mohsen Yaghoubi & Sonya Cressman & Louisa Edwards & Steven Shechter & Mary M. Doyle-Waters & Paul Keown & Ruth Sapir-Pichhadze & Stirling Bryan - 53-70 Economic Evaluations of Preventive Interventions for Dental Caries and Periodontitis: A Systematic Review
by Tan Minh Nguyen & Utsana Tonmukayakul & Long Khanh-Dao Le & Hanny Calache & Cathrine Mihalopoulos - 71-89 Determinants of COVID-19 Vaccine Rollouts and Their Effects on Health Outcomes
by Pragyan Deb & Davide Furceri & Daniel Jimenez & Siddharth Kothari & Jonathan D. Ostry & Nour Tawk - 91-107 What Features of Fertility Treatment do Patients Value? Price Elasticity and Willingness-to-Pay Values from a Discrete Choice Experiment
by Elena Keller & Willings Botha & Georgina M. Chambers - 109-118 Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes Patients
by Anna-Katharina Böhm & Udo Schneider & Tom Stargardt - 119-130 Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis
by Christian Domingo & Mario Fernandez & Noe Garin & Javier Milara & Ignacio Moran & Irantzu Muerza & Adalberto Pacheco & Carlos Teruel & Roy Bentley & Rafael Subiran & Alicia Gil - 131-140 Financing Comprehensive Immunization Services in Lao PDR: A Fiscal Space Analysis From a Public Policy Perspective
by Pankaj Bahuguna & Emiko Masaki & Gursimer Jeet & Shankar Prinja - 141-152 Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis
by Kangho Suh & Brian J. Cole & Andreas Gomoll & Seung-Mi Lee & Hangseok Choi & Chul-Won Ha & Hong Chul Lim & Myung Ku Kim & Gwi-Yeom Ha & Dong-Churl Suh - 153-153 Correction to: Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis
by Kangho Suh & Brian J. Cole & Andreas Gomoll & Seung-Mi Lee & Hangseok Choi & Chul-Won Ha & Hong Chul Lim & Myung Ku Kim & Gwi-Yeom Ha & Dong-Churl Suh
November 2022, Volume 20, Issue 6
- 783-792 Economic Evaluation Evidence for Resource-Allocation Decision Making: Bridging the Gap for Local Decision Makers Using English Case Studies
by Daniel Howdon & Sebastian Hinde & James Lomas & Matthew Franklin - 793-802 Health Inequalities: To What Extent are Decision-Makers and Economic Evaluations on the Same Page? An English Case Study
by Sebastian Hinde & Dan Howdon & James Lomas & Matthew Franklin - 803-817 Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines
by Yannick Vandenplas & Steven Simoens & Florian Turk & Arnold G. Vulto & Isabelle Huys - 819-834 Systematic Review and Quality Assessment of Health Economic Evaluation Studies (2007–2019) Conducted in South Korea
by Sunghyun Yi & Jihyung Hong & Haemin Yoon & You-na Lim & Eun-Young Bae - 835-843 Cost-Effectiveness Analysis of Temocillin Treatment in Patients with Febrile UTI Accounting for the Emergence of Antibiotic Resistance
by Sofie Larsson & Charlotta Edlund & Pontus Nauclér & Mikael Svensson & Anders Ternhag - 845-856 Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study
by Ze Cong & Oth Tran & James Nelson & Monica Silver & Karen Chung - 857-866 Evaluating Health Inequality in Five Caribbean Basin Countries Using EQ-5D-5L
by Henry H. Bailey & Mathieu F. Janssen & Fareena M. Alladin & Althea Foucade & Rodrigo Varela & Jhon A. Moreno & Marjorie Wharton & Philip Castillo & Girjanauth Boodraj - 867-880 Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach
by Bettina Wulff Risør & Nasrin Tayyari Dehbarez & Jacob Fredsøe & Karina Dalsgaard Sørensen & Bodil Ginnerup Pedersen - 881-891 Estimating the Health Effects of Expansions in Health Expenditure in Indonesia: A Dynamic Panel Data Approach
by Silvia Moler-Zapata & Noémi Kreif & Jessica Ochalek & Andrew J. Mirelman & Mardiati Nadjib & Marc Suhrcke - 893-904 Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China
by Ziping Ye & Raela Abduhilil & Jiaxin Huang & Lihua Sun - 905-917 Cost-Utility Analysis of Major System Change in Specialist Cancer Surgery in London, England, Using Linked Patient-Level Electronic Health Records and Difference-in-Differences Analysis
by Caroline S. Clarke & Mariya Melnychuk & Angus I. G. Ramsay & Cecilia Vindrola-Padros & Claire Levermore & Ravi Barod & Axel Bex & John Hines & Muntzer M. Mughal & Kathy Pritchard-Jones & Maxine Tran & David C. Shackley & Stephen Morris & Naomi J. Fulop & Rachael M. Hunter
September 2022, Volume 20, Issue 5
- 625-628 Including Pharmaceuticals in Bundled Payments
by Gerard F. Anderson & Andrew York & Joshua L. Choe - 629-635 Using Economics to Impact Local Obesity Policy: Introducing the UK Centre for Economics of Obesity (CEO)
by Emma Frew & Nafsika Afentou & Hamideh Mohtashami Borzadaran & Paolo Candio & Irina Pokhilenko - 637-650 Centralised Pharmaceutical Procurement: Learnings from Six European Countries
by Sabine Vogler & Eveli Bauer & Katharina Habimana - 651-667 Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
by Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse - 669-680 UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update
by Laura Knight & Megan Dale & Andrew Cleves & Charlotte Pelekanou & Rhys Morris - 681-691 An Economic Evaluation of Government-Funded COVID-19 Testing in Australia
by Jonathan Karnon & Hossein Haji Ali Afzali & Billie Bonevski - 693-706 Information Asymmetry in Hospitals: Evidence of the Lack of Cost Awareness in Clinicians
by Jeremy Fabes & Tuba Saygın Avşar & Jonathan Spiro & Thomas Fernandez & Helge Eilers & ·Steve Evans & Amelia Hessheimer & Paula Lorgelly & Michael Spiro - 707-716 Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi
by Fulgence Niyibitegeka & Montarat Thavorncharoensap & Arthorn Riewpaiboon & Sitaporn Youngkong - 717-729 Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers
by Renée E. Michels & Carlos H. Arteaga & Michel L. Peters & Ellen Kapiteijn & Carla M. L. Herpen & Marieke Krol - 731-742 ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients
by Kristyna Lacinova & Praveen Thokala & Richard Nicholas & Pamela Dobay & Erik Scalfaro & Zuzanna Angehrn & Roisin Brennan & Ibolya Boer & Carol Lines & Nicholas Adlard - 743-755 Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model
by Jia Liu & Xiaoning He & Jing Wu - 757-768 Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
by Daniel Tobias Michaeli & Mackenzie Mills & Panos Kanavos - 769-779 Cost-Effectiveness and Budget Impact Analysis of Implementing a 'Soft Opt-Out' System for Kidney Donation in Australia
by Sameera Senanayake & Helen Healy & Steven M. McPhail & Keshwar Baboolal & Sanjeewa Kularatna - 781-782 Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
by Don Husereau & Michael Drummond & Federico Augustovski & Esther Bekker-Grob & Andrew H. Briggs & Chris Carswell & Lisa Caulley & Nathorn Chaiyakunapruk & Dan Greenberg & Elizabeth Loder & Josephine Mauskopf & C. Daniel Mullins & Stavros Petrou & Raoh-Fang Pwu & Sophie Staniszewska
July 2022, Volume 20, Issue 4
- 453-455 Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid?
by Livio Garattini & Bruno Finazzi - 457-465 Data-Related Challenges in Cost-Effectiveness Analyses of Vaccines
by Jamison Pike & Andrew J. Leidner & Harrell Chesson & Charles Stoecker & Scott D. Grosse - 467-477 Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version
by Eun-Young Bae & Jihyung Hong & SeungJin Bae & Seokyung Hahn & Hyonggin An & Eun-joo Hwang & Seung-min Lee & Tae-jin Lee - 479-486 Modelling the Future Clinical and Economic Burden of Antimicrobial Resistance: The Feasibility and Value of Models to Inform Policy
by Nadine T. Hillock & Tracy L. Merlin & John Turnidge & Jonathan Karnon - 487-499 A Case Study on Reviewing Specialist Services Commissioning in Wales: TAVI for Severe Aortic Stenosis
by Edyta Ryczek & Susan C. Peirce & Laura Knight & Andrew Cleves & Andrew Champion & Iolo Doull & Sian Lewis - 501-524 Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options
by Rositsa Koleva-Kolarova & James Buchanan & Heleen Vellekoop & Simone Huygens & Matthijs Versteegh & Maureen Rutten-van Mölken & László Szilberhorn & Tamás Zelei & Balázs Nagy & Sarah Wordsworth & Apostolos Tsiachristas - 525-541 What Policy Approaches Were Effective in Reducing Catastrophic Health Expenditure? A Systematic Review of Studies from Multiple Countries
by HyunWoo Jung & Kwang-Soo Lee - 543-555 Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
by Sara Stafford & Peter G. Bech & Adam Fridhammar & Nino Miresashvili & Andreas Nilsson & Michael Willis & Aiden Liu - 557-572 How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15
by Stephen Martin & Karl Claxton & James Lomas & Francesco Longo - 573-585 Population Norms for SF-6Dv2 and EQ-5D-5L in China
by Shitong Xie & Jing Wu & Feng Xie - 587-596 Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand
by Piyameth Dilokthornsakul & Ratree Sawangjit & Pisit Tangkijvanich & Maneerat Chayanupatkul & Tawesak Tanwandee & Wattana Sukeepaisarnjaroen & Pajaree Sriuttha & Unchalee Permsuwan - 597-607 Preferred Attributes of Care Pathways for Obstructive Sleep Apnoea from the Perspective of Diagnosed Patients and High-Risk Individuals: A Discrete Choice Experiment
by Andrea N. Natsky & Andrew Vakulin & Ching Li Chai-Coetzer & R. Doug McEvoy & Robert J. Adams & Billingsley Kaambwa - 609-621 Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women
by Nidhi Gupta & Dharna Gupta & Jyoti Dixit & Nikita Mehra & Ashish Singh & Manjunath Nookala Krishnamurthy & Gaurav Jyani & Kavitha Rajsekhar & Jayachandran Perumal Kalaiyarasi & Partha Sarathi Roy & Prabhat Singh Malik & Anisha Mathew & Pankaj Malhotra & Sudeep Gupta & Lalit Kumar & Amal Kataki & Shankar Prinja - 623-623 Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
by Sara Stafford & Peter G. Bech & Adam Fridhammar & Nino Miresashvili & Andreas Nilsson & Michael Willis & Aiden Liu
May 2022, Volume 20, Issue 3
- 287-290 How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
by Charalabos-Markos Dintsios & Nadja Chernyak - 291-303 Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?
by Sándor Kovács & Bertalan Németh & Dalma Erdősi & Valentin Brodszky & Imre Boncz & Zoltán Kaló & Antal Zemplényi - 305-313 Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance
by Ruth Louise Poole & Megan Dale & Helen Morgan & Tosin Oladapo & Rebecca Brookfield & Rhys Morris - 315-335 A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa
by Mouaddh Abdulmalik Nagi & Pramitha Esha Nirmala Dewi & Montarat Thavorncharoensap & Sermsiri Sangroongruangsri - 337-349 Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries
by Laura Vallejo-Torres & Borja García-Lorenzo & Laura Catherine Edney & Niek Stadhouders & Ijeoma Edoka & Iván Castilla-Rodríguez & Lidia García-Pérez & Renata Linertová & Cristina Valcárcel-Nazco & Jonathan Karnon - 351-370 Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review
by Jiayu Shi & Kenan Fan & Lei Yan & Zijuan Fan & Fei Li & Guishan Wang & Haifeng Liu & Peidong Liu & Hongmei Yu & Jiao Jiao Li & Bin Wang - 371-381 Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India
by V. Srinivasan & David E. Bloom & Alex Khoury - 383-393 Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents
by Mimmi Åström & Ola Rolfson & Kristina Burström - 395-404 Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries
by Siyu Ma & Tara A. Lavelle & Daniel A. Ollendorf & Pei-Jung Lin - 405-416 How Did the Affordable Care Act Affect Risky Health Behaviors?
by Cagdas Agirdas - 417-429 Scope Issue in Contingent Valuation Studies of the COVID-19 Vaccine: The Case of China
by Jianhong Xiao & Yihui Wu & Min Wang & Zegang Ma - 431-445 Cost-effectiveness Analysis of the Dental RECUR Pragmatic Randomized Controlled Trial: Evaluating a Goal-oriented Talking Intervention to Prevent Reoccurrence of Dental Caries in Children
by Ezeofor Victory & Edwards T. Rhiannon & Burnside Girvan & Adair Pauline & Pine M. Cynthia - 447-449 Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?
by Howard Thom - 451-451 Correction to: Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?
by Howard Thom
March 2022, Volume 20, Issue 2
- 145-147 Integrated Care in Europe: Time to Get it Together?
by Livio Garattini & Marco Badinella Martini & Alessandro Nobili - 149-158 From Spreadsheets to Script: Experiences From Converting a Scottish Cardiovascular Disease Policy Model into R
by Yiqiao Xin & Ewan Gray & Jose Antonio Robles-Zurita & Houra Haghpanahan & Robert Heggie & Ciaran Kohli-Lynch & Andrew Briggs & David A. McAllister & Kenny D. Lawson & Jim Lewsey - 159-169 Episcissors-60 for Mediolateral Episiotomy: Evaluation of Clinical and Economic Evidence to Inform NICE Medical Technologies Guidance
by Susan O’Connell & Megan Dale & Helen Morgan & Bernice Dillon & Andrew Cleves & Rhys Morris & Grace Carolan-Rees - 171-183 Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations
by Paul G. Carty & Christopher G. Fawsitt & Paddy Gillespie & Patricia Harrington & Michelle O’Neill & Susan M. Smith & Conor Teljeur & Mairin Ryan - 185-198 The Cost Effectiveness of Taxation of Sugary Foods and Beverages: A Systematic Review of Economic Evaluations
by Siyuan Liu & Paul J. Veugelers & Chunhao Liu & Arto Ohinmaa - 199-212 The Effect of Price Changes and Teaspoon Labelling on Intention to Purchase Sugar-Sweetened Beverages: A Discrete Choice Experiment
by Vinh Vo & K.-H. Nguyen & J. A. Whitty & Tracy A. Comans - 213-221 Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
by Don Husereau & Michael Drummond & Federico Augustovski & Esther Bekker-Grob & Andrew H. Briggs & Chris Carswell & Lisa Caulley & Nathorn Chaiyakunapruk & Dan Greenberg & Elizabeth Loder & Josephine Mauskopf & C. Daniel Mullins & Stavros Petrou & Raoh-Fang Pwu & Sophie Staniszewska - 223-233 The Effects of School Closures on COVID-19: A Cross-Country Panel Analysis
by Vincenzo Alfano - 235-241 Are Medical Devices Cost-Effective?
by James D. Chambers & Madison C. Silver & Flora C. Berklein & Joshua T. Cohen & Peter J. Neumann - 243-253 Effect of Competition on Generic Drug Prices
by Nguyen Xuan Nguyen & Steven H. Sheingold & Wafa Tarazi & Arielle Bosworth - 255-267 Willingness to Pay for National Health Insurance: A Contingent Valuation Study Among Patients Visiting Public Hospitals in Melaka, Malaysia
by Robin Tiow Heng Tan & Siti Zaleha Abdul Rasid & Wan Khairuzzaman Wan Ismail & Janiza Tobechan & Edwin Tiow Yong Tan & Alia Natasha Yusof & Jia Hui Low - 269-282 Cost-Utility Analysis of Discontinuing Antidepressants in England Primary Care Patients Compared with Long-Term Maintenance: The ANTLER Study
by Caroline S. Clarke & Larisa Duffy & Glyn Lewis & Nick Freemantle & Simon Gilbody & Tony Kendrick & David Kessler & Michael King & Paul Lanham & Derelie Mangin & Michael Moore & Irwin Nazareth & Nicola Wiles & Louise Marston & Rachael Maree Hunter - 283-283 Correction to: Cost-Utility Analysis of Discontinuing Antidepressants in England Primary Care Patients Compared with Long-Term Maintenance: The ANTLER Study
by Caroline S. Clarke & Larisa Duffy & Glyn Lewis & Nick Freemantle & Simon Gilbody & Tony Kendrick & David Kessler & Michael King & Paul Lanham & Derelie Mangin & Michael Moore & Irwin Nazareth & Nicola Wiles & Louise Marston & Rachael Maree Hunter - 285-285 Correction to: The Cost Effectiveness of Taxation of Sugary Foods and Beverages: A Systematic Review of Economic Evaluations
by Siyuan Liu & Paul J. Veugelers & Chunhao Liu & Arto Ohinmaa
January 2022, Volume 20, Issue 1
- 5-8 Financial Incentives in the Path to Recovery from the COVID-19 Pandemic
by Afschin Gandjour - 9-11 Strategies for Avoiding Neglect of Opportunity Costs by Decision-Makers
by Jonathan Karnon & Andrew Partington & Hossein Afzali - 13-18 Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment
by James Lomas & Jessica Ochalek & Rita Faria - 19-33 Approaches to Measure Efficiency in Primary Care: A Systematic Literature Review
by Margherita Neri & Patricia Cubi-Molla & Graham Cookson - 35-54 Quality of Health Economic Evaluations in Mainland China: A Comparison of Peer-Reviewed Articles in Chinese and in English
by Jiehua Cheng & Yu Zhang & Ailin Zhong & Miao Tian & Guanyang Zou & Xiaping Chen & Hongxing Yu & Fujian Song & Shangcheng Zhou - 55-65 Is There Broad-Based Support in High-Income Countries for COVID-19 Vaccine Donation? Evidence from Seven Countries
by Laurence S. J. Roope & Adrian Barnett & Paolo Candio & Mara Violato & Raymond Duch & Philip M. Clarke - 67-77 Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America
by Daniela Moye-Holz & S. Vogler - 79-89 Economic Evaluation of an Intervention Designed to Reduce Bullying in Australian Schools
by Amarzaya Jadambaa & Nicholas Graves & Donna Cross & Rosana Pacella & Hannah J. Thomas & James G. Scott & Qinglu Cheng & David Brain - 91-104 Costs and Cost-Effectiveness of User-Testing of Health Professionals’ Guidelines to Reduce the Frequency of Intravenous Medicines Administration Errors by Nurses in the United Kingdom: A Probabilistic Model Based on Voriconazole Administration
by Matthew D. Jones & Bryony Dean Franklin & D. K. Raynor & Howard Thom & Margaret C. Watson & Rebecca Kandiyali - 105-117 Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward
by Eleanor Bell & Margherita Neri & Lotte Steuten - 119-131 Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores
by Aurelie Meunier & Alexandra Soare & Helene Chevrou-Severac & Karl-Johan Myren & Tatsunori Murata & Louise Longworth - 133-143 Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis
by Andrea Marcellusi & Claudia Simonelli & Francesco S. Mennini & Loreta A. Kondili
November 2021, Volume 19, Issue 6
- 785-788 Towards a New Understanding of Unmet Medical Need
by Kyann Zhang & Gayathri Kumar & Chris Skedgel - 789-795 Methodological Note: Reporting Deterministic versus Probabilistic Results of Markov, Partitioned Survival and Other Non-Linear Models
by Edward C. F. Wilson - 797-810 How to Cost the Implementation of Major System Change for Economic Evaluations: Case Study Using Reconfigurations of Specialist Cancer Surgery in Part of London, England
by Caroline S. Clarke & Cecilia Vindrola-Padros & Claire Levermore & Angus I. G. Ramsay & Georgia B. Black & Kathy Pritchard-Jones & John Hines & Gillian Smith & Axel Bex & Muntzer Mughal & David Shackley & Mariya Melnychuk & Steve Morris & Naomi J. Fulop & Rachael M. Hunter - 811-823 National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India
by Shankar Prinja & Yashika Chugh & Kavitha Rajsekar & V. R. Muraleedharan - 825-838 Systematic Literature Review of Guidelines on Budget Impact Analysis for Health Technology Assessment
by Yashika Chugh & Maria Francesco & Shankar Prinja - 839-855 Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta-analysis
by Leila Doshmangir & Edris Hasanpoor & Gerard Joseph Abou Jaoude & Behzad Eshtiagh & Hassan Haghparast-Bidgoli - 857-869 The Sandbox Approach and its Potential for Use in Health Technology Assessment: A Literature Review
by Emily Leckenby & Dalia Dawoud & Jacoline Bouvy & Páll Jónsson - 871-883 COVID-19 Vaccine Demand and Financial Incentives
by Carlos E. Carpio & Ioana A. Coman & Oscar Sarasty & Manuel García - 885-903 How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13
by Stephen Martin & James Lomas & Karl Claxton & Francesco Longo - 905-914 EQ-5D-5L Health-State Values for the Mexican Population
by Cristina Gutierrez-Delgado & Rosa-María Galindo-Suárez & Cesar Cruz-Santiago & Koonal Shah & Manny Papadimitropoulos & Yan Feng & Bernarda Zamora & Nancy Devlin - 915-927 Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe
by Luka Vončina & Tea Strbad & Jurij Fürst & Maria Dimitrova & Maria Kamusheva & Megi Vila & Ileana Mardare & Kristina Hristova & Andras Harsanyi & Dragana Atanasijević & Igor Banović & Ana Bobinac - 929-940 Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
by B. Muresan & C. Mamolo & J. C. Cappelleri & M. J. Postma & B. Heeg - 941-951 The Health and Productivity Burden of Depression in South Korea
by Ella Zomer & YongJoo Rhee & Danny Liew & Zanfina Ademi - 953-953 Correction to: Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta‑analysis
by Leila Doshmangir & Edris Hasanpoor & Gerard Joseph Abou Jaoude & Behzad Eshtiagh & Hassan Haghparast-Bidgoli
September 2021, Volume 19, Issue 5
- 625-634 Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies
by Jennifer G. Gaultney & Jacoline C. Bouvy & Richard H. Chapman & Alexander J. Upton & Stacey Kowal & Carsten Bokemeyer & Oriol Solà-Morales & Jürgen Wolf & Andrew H. Briggs - 635-644 Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
by Patricia Cubi-Molla & Martin Buxton & Nancy Devlin - 645-651 A Review of Web-Based Tools for Value-of-Information Analysis
by Haitham Tuffaha & Claire Rothery & Natalia Kunst & Chris Jackson & Mark Strong & Stephen Birch - 653-664 ‘What You See is All There is’: The Importance of Heuristics in Cost-Benefit Analysis (CBA) and Social Return on Investment (SROI) in the Evaluation of Public Health Interventions
by Rhiannon Tudor Edwards & Catherine Louise Lawrence - 665-672 The PLASMA System for Transurethral Resection of the Prostate: A NICE Medical Technologies Guidance Update
by Laura Knight & Susan Peirce & Rhys Morris - 673-697 A Systematic Review of the Costs Relating to Non-pharmaceutical Interventions Against Infectious Disease Outbreaks
by Janetta E. Skarp & Laura E. Downey & Julius W. E. Ohrnberger & Lucia Cilloni & Alexandra B. Hogan & Abagael L. Sykes & Susannah S. Wang & Hiral Anil Shah & Mimi Xiao & Katharina Hauck - 699-708 Using Constrained Optimization for the Allocation of COVID-19 Vaccines in the Philippines
by Christian Alvin H. Buhat & Destiny S. M. Lutero & Yancee H. Olave & Kemuel M. Quindala & Mary Grace P. Recreo & Dylan Antonio S. J. Talabis & Monica C. Torres & Jerrold M. Tubay & Jomar F. Rabajante - 709-719 How Much Money Should be Paid for a Patient to Isolate During the COVID-19 Outbreak? A Discrete Choice Experiment in Iran
by Enayatollah Homaie Rad & Mohammad Hajizadeh & Vahid Yazdi-Feyzabadi & Sajad Delavari & Zahra Mohtasham-Amiri - 721-733 The Impact of Financing Health Services on Income Inequality in an Unequal Society: The Case of South Africa
by John E. Ataguba - 735-745 Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
by Han Geul Byun & Minyoung Jang & Hyun Kyeong Yoo & James Potter & Taek Sang Kwon - 747-756 Incorporating Process Utility into Cost-Effectiveness Analysis via a Bolt-On Domain to the SF-6D: An Exploratory Study
by Victoria K. Brennan & Georgina Jones & Stephen Radley & Simon Dixon - 757-767 Consumers' Preferences and Willingness to Pay for Personalised Nutrition
by Daniel Pérez-Troncoso & David M. Epstein & José A. Castañeda-García - 769-782 Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data
by Jeetendra Yadav & Geetha R. Menon & Denny John - 783-784 Comment on: “Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data”
by Nafis Faizi & Yasir Alvi
July 2021, Volume 19, Issue 4
- 453-461 Cost of Medicare for All: Review of the Estimates
by John A. Nyman - 463-472 Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines
by Chris Painter & Wanrudee Isaranuwatchai & Juthamas Prawjaeng & Hwee Lin Wee & Brandon Wen Bing Chua & Vinh Anh Huynh & Jing Lou & Fang Ting Goh & Nantasit Luangasanatip & Wirichada Pan-Ngum & Wang Yi & Hannah Clapham & Yot Teerawattananon - 473-486 Cost-effectiveness of Interventions for Chronic Fatigue Syndrome or Myalgic Encephalomyelitis: A Systematic Review of Economic Evaluations
by M. Cochrane & E. Mitchell & W. Hollingworth & E. Crawley & D. Trépel - 487-499 Economic Analyses of Pathogen-Reduction Technologies in Blood Transfusion: A Systematic Literature Review
by Patrick R. LaFontaine & Jing Yuan & Katherine M. Prioli & Priti Shah & Jay H. Herman & Laura T. Pizzi - 501-520 Costs of Illness of Spinal Muscular Atrophy: A Systematic Review
by Erik Landfeldt & Astrid Pechmann & Hugh J. McMillan & Hanns Lochmüller & Thomas Sejersen - 521-535 Preferences for Medical Consultations from Online Providers: Evidence from a Discrete Choice Experiment in the United Kingdom
by James Buchanan & Laurence S. J. Roope & Liz Morrell & Koen B. Pouwels & Julie V. Robotham & Lucy Abel & Derrick W. Crook & Tim Peto & Christopher C. Butler & A. Sarah Walker & Sarah Wordsworth - 537-544 Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis
by George Dranitsaris & Carlo DeAngelis & Blake Pearson & Laura McDermott & Bernd Pohlmann-Eden - 545-555 Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea
by Siin Kim & Sola Han & Hyungtae Kim & Hae Sun Suh - 557-577 The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil
by Wânia Cristina Silva & Brian Godman & Francisco Acúrcio & Mariângela Leal Cherchiglia & Antony Martin & Konrad Maruszczyk & Jans Bastos Izidoro & Marcos André Portella & Agner Pereira Lana & Orozimbo Henriques Campos Neto & Eli Iola Gurgel Andrade - 579-591 The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data
by Cathrine Elgaard Jensen & Sabrina Storgaard Sørensen & Claire Gudex & Morten Berg Jensen & Kjeld Møller Pedersen & Lars Holger Ehlers - 593-604 Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn’s Disease
by Tomas Mlcoch & Barbora Decker & Tomas Dolezal - 605-618 Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives
by Jingyan Yang & Rongzhe Liu & Varun Ektare & Jennifer Stephens & Ahmed Shelbaya - 619-621 Comment on: “Willingness to Pay for a COVID-19 Vaccine”
by Philipp Sprengholz & Cornelia Betsch - 623-624 Authors’ Reply to Sprengholz and Betsch: “Willingness to Pay for a COVID-19 Vaccine”
by Leidy Y. García & Arcadio A. Cerda
May 2021, Volume 19, Issue 3
- 281-304 Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries
by Yitong Wang & Tingting Qiu & Junwen Zhou & Clément Francois & Mondher Toumi - 305-312 Copula Models for Addressing Sample Selection in the Evaluation of Public Health Programmes: An Application to the Leeds Let’s Get Active Study
by Paolo Candio & Andrew J. Hill & Stavros Poupakis & Anni-Maria Pulkki-Brännström & Chris Bojke & Manuel Gomes - 313-324 The Cost-Effectiveness of Pulmonary Rehabilitation for COPD in Different Settings: A Systematic Review
by Shengnan Liu & Qiheng Zhao & Wenshuo Li & Xuetong Zhao & Kun Li - 325-341 The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review
by Nicolas Iragorri & Claire Oliveira & Natalie Fitzgerald & Beverley Essue - 343-351 Willingness to Pay for a COVID-19 Vaccine
by Arcadio A. Cerda & Leidy Y. García - 353-370 Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India's National Publicly Financed Health Insurance Scheme
by Shankar Prinja & Maninder Pal Singh & Kavitha Rajsekar & Oshima Sachin & Praveen Gedam & Anu Nagar & Balram Bhargava - 371-387 Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C
by Pingyu Chen & Min Jin & Yang Cao & Hongchao Li - 389-401 What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches
by Anthony J. Hatswell & Ash Bullement & Michael Schlichting & Murtuza Bharmal - 403-414 Potential Unintended Consequences of National Infectious Disease Screening Strategies in Deceased Donor Kidney Transplantation: A Cost-Effectiveness Analysis
by Trevor A. Ellison & Samantha Clark & Jonathan C. Hong & Kevin D. Frick & Dorry L. Segev - 415-428 Prescription Drug Monitoring Programs and Opioid Prescriptions for Disability Conditions
by Orgul Ozturk & Yuan Hong & Suzanne McDermott & Margaret Turk - 429-437 Management of Chest Indrawing Pneumonia in Children Under Five Years at the Outpatient Health Facilities in Nigeria: An Economic Evaluation
by Charles E. Okafor - 439-450 Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies
by Sun-Hong Kwon & Hea-Sun Park & Young-Jin Na & Chul Park & Ju-Young Shin & Hye-Lin Kim - 451-451 Correction to: Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India’s National Publicly Financed Health Insurance Scheme
by Shankar Prinja & Maninder Pal Singh & Kavitha Rajsekar & Oshima Sachin & Praveen Gedam & Anu Nagar & Balram Bhargava
March 2021, Volume 19, Issue 2
- 141-144 The Vatican City State Internal Healthcare System Response to COVID-19 Pandemic: Prevention and Control Strategies
by Andrea Arcangeli & Massimo Ralli & Fabio De-Giorgio & Paolo Maurizio Soave & Lucia Ercoli - 145-153 Curos™ Disinfection Caps for the Prevention of Infection When Using Needleless Connectors: A NICE Medical Technologies Guidance
by Susan O’Connell & Megan Dale & Helen Morgan & Kimberley Carter & Grace Carolan-Rees - 155-162 Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review
by William V. Padula & Hui-Han Chen & Charles E. Phelps - 163-180 The Cost-Effectiveness of Kidney Replacement Therapy Modalities: A Systematic Review of Full Economic Evaluations
by Fei Yang & Meixia Liao & Pusheng Wang & Zheng Yang & Yongguang Liu - 181-190 How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany
by Afschin Gandjour - 191-202 French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30
by Virginie Nerich & Eva Maria Gamper & Richard Norman & Madeleine King & Bernhard Holzner & Rosalie Viney & Georg Kemmler - 203-215 Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD
by Kate M. Johnson & Mohsen Sadatsafavi & Amin Adibi & Larry Lynd & Mark Harrison & Hamid Tavakoli & Don D. Sin & Stirling Bryan - 217-229 Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
by Mujaheed Shaikh & Pietro Giudice & Dimitrios Kourouklis - 231-241 Budget Impact of Microbial Cell-Free DNA Testing Using the Karius® Test as an Alternative to Invasive Procedures in Immunocompromised Patients with Suspected Invasive Fungal Infections
by Ann T. MacIntyre & Alex Hirst & Radha Duttagupta & Desiree Hollemon & David K. Hong & Timothy A. Blauwkamp - 243-252 Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UK
by Rucha Vadia & Tom Stargardt - 253-266 Identifying Community Pharmacist Preferences For Prescribing Services in Primary Care in New Zealand: A Discrete Choice Experiment
by Rakhee Raghunandan & Kirsten Howard & Carlo A. Marra & June Tordoff & Alesha Smith - 267-277 Cost Effectiveness of Introducing Etonorgestrel Contraceptive Implant into India’s Current Family Welfare Programme
by Beena Joshi & Kusum V. Moray & Oshima Sachin & Himanshu Chaurasia & Shahina Begum - 279-279 Correction to: Cost Effectiveness of Introducing Etonorgestrel Contraceptive Implant into India’s Current Family Welfare Programme
by Beena Joshi & Kusum V. Moray & Oshima Sachin & Himanshu Chaurasia & Shahina Begum
January 2021, Volume 19, Issue 1
- 5-8 Economic Theory and Medical Assistance in Dying
by Donald A. Redelmeier & Allan S. Detsky - 9-15 Using a Formal Strategy of Priority Setting to Mitigate Austerity Effects Through Gains in Value: The Role of Program Budgeting and Marginal Analysis (PBMA) in the Brazilian Public Healthcare System
by Brayan V. Seixas & Craig Mitton - 17-27 Systematic Review and Critique of Methods for Economic Evaluation of Digital Mental Health Interventions
by Dina Jankovic & Laura Bojke & David Marshall & Pedro Saramago Goncalves & Rachel Churchill & Hollie Melton & Sally Brabyn & Lina Gega - 29-44 Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results
by Ru Han & Clément François & Mondher Toumi - 45-56 Elections have Consequences: Partisan Politics may be Literally Killing Us
by Alexander Maas & Liang Lu - 57-68 Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator
by Moritz Hadwiger & Fabian-Simon Frielitz & Nora Eisemann & Christian Elsner & Nikolaos Dagres & Gerhard Hindricks & Alexander Katalinic - 69-79 Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
by Shanshan Hu & Xun Deng & Yanjiao Ma & Zhilei Li & Yuhang Wang & Yong Wang - 81-96 Availability and Variability of Consumer Prices for Lumbar Discectomy Across US Hospitals in 2018
by Alexander J. Butler & Caroline J. Granger & Sebastian Rivera & Chester J. Donnally & Alexander Ghasem & Deborah Li & Michael Y. Wang - 97-109 Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer
by Julia Simoes Correa-Galendi & Maria Pilar Estevez Diz & Stephanie Stock & Dirk Müller - 111-121 Using Eye-Tracking Technology with Older People in Memory Clinics to Investigate the Impact of Mild Cognitive Impairment on Choices for EQ-5D-5L Health States Preferences
by Kaiying Wang & Chris Barr & Richard Norman & Stacey George & Craig Whitehead & Julie Ratcliffe - 123-132 Economic Evaluation of Senshio® (Ospemifene) for the Treatment of Vulvovaginal Atrophy in Scotland
by Amy Dymond & Hayden Holmes & Jessica McMaster & Joyce Craig & Heather Davies & Stuart Mealing & Rodolphe Perard